Raymond James analyst John Ransom lowered its price target on CVS Health (NYSE:CVS) to $110 from $115 and maintained the stock’s “outperform” rating. The analyst told investors in a research note that CVS Health’s fourth-quarter results were in line with their pre-announcement, that guidance for 2023 remained unchanged, and that the company announced the acquisition of Oak Street Health, a health firm on Oak Street.